We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App





Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022

Meridian Bioscience Inc. More...

(Cincinnati, OH, USA) is attending the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo where the company will exhibit its state-of-the-art urea breath test system alongside its advanced fluorescent immunoassay and molecular platforms.

At AACC 2022, Meridian will display its state-of-the-art BreathID Hp Lab urea breath test system for H. pylori detection that intuitively combines market-leading diagnostic accuracy with efficient automation and fast batch-test analysis for maximizing large lab testing throughput. The system’s built-in automated monitoring manages batch analysis, moving from test sample to test sample while noting any sample errors for post-batch handling. The BreathID platform can be used in conjunction with other Meridian H. pylori platforms for a total testing solution across the health system.

Meridian is also exhibiting the Curian fluorescent immunoassay platform focused on gastrointestinal testing that is packaged in a small footprint to improve hospital operational efficiencies. Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. Laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care.

Also on display at Meridian’s booth will be the company’s Revogene flexible molecular platform capable of single analyte and multiplex testing that is packaged in a small footprint, and can help standardize testing throughout the health system. Revogene is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. The flexible, scalable platform comes with a broad test menu for the detection of hospital inquired infections, gastrointestinal, respiratory, and neonatal diseases.
 

Related Links:
Meridian Bioscience Inc. 


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The mRNA Gene Biomarker Test uses standard blood samples to generate a probability score distinguishing schizophrenia from bipolar I disorder (photo courtesy of Laguna Diagnostics)

Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder

Differentiating schizophrenia from bipolar I disorder in symptomatic patients is challenging because early presentations often overlap. Current diagnostic pathways rely heavily on subjective assessments... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.